Literature DB >> 18831576

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.

Giorgio Ortar1, Tiziana Bisogno, Alessia Ligresti, Enrico Morera, Marianna Nalli, Vincenzo Di Marzo.   

Abstract

A series of 21 analogues of tetrahydrolipstatin (THL, 1) were synthesized and tested as inhibitors of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Three of the novel compounds, i.e., 11, 13, and 15, inhibited 2-AG formation via the diacylglycerol lipase alpha (DAGLalpha) with IC 50 values lower than 50 nM (IC 50 of THL = 1 microM) and were between 23- and 375-fold selective vs 2-AG hydrolysis by monoacylglycerol lipase (MAGL) as well as vs cannabinoid CB 1 and CB 2 receptors and anandamide hydrolysis by fatty acid amide hydrolase (FAAH). Three other THL analogues, i.e., 14, 16, and 18, were slightly more potent than THL against DAGLalpha and appreciably selective vs MAGL, CB receptors, and FAAH (15-26-fold). One compound, i.e., 8, was a potent inhibitor of MAGL-like activity (IC 50 = 0.41 microM), and relatively ( approximately 7-fold) selective vs the other targets tested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831576     DOI: 10.1021/jm800978m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight.

Authors:  Vincenzo Di Marzo
Journal:  Nat Neurosci       Date:  2011-01       Impact factor: 24.884

2.  Associative, bidirectional changes in neural signaling utilizing NMDA receptor- and endocannabinoid-dependent mechanisms.

Authors:  Qin Li; Brian D Burrell
Journal:  Learn Mem       Date:  2011-08-15       Impact factor: 2.460

Review 3.  Monoacylglycerol lipase - a target for drug development?

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  Assay and inhibition of diacylglycerol lipase activity.

Authors:  Meghan Johnston; Shachi R Bhatt; Surina Sikka; Richard W Mercier; Jay M West; Alexandros Makriyannis; S John Gatley; Richard I Duclos
Journal:  Bioorg Med Chem Lett       Date:  2012-06-06       Impact factor: 2.823

Review 5.  Chemical modulation of glycerolipid signaling and metabolic pathways.

Authors:  Sarah A Scott; Thomas P Mathews; Pavlina T Ivanova; Craig W Lindsley; H Alex Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-15

6.  Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation.

Authors:  M Bashashati; Y Nasser; C M Keenan; W Ho; F Piscitelli; M Nalli; K Mackie; M A Storr; V Di Marzo; K A Sharkey
Journal:  Br J Pharmacol       Date:  2015-04-23       Impact factor: 8.739

7.  Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.

Authors:  Rosaria I Staiano; Stefania Loffredo; Francesco Borriello; Fabio Arturo Iannotti; Fabiana Piscitelli; Pierangelo Orlando; Agnese Secondo; Francescopaolo Granata; Maria Teresa Lepore; Alfonso Fiorelli; Gilda Varricchi; Mario Santini; Massimo Triggiani; Vincenzo Di Marzo; Gianni Marone
Journal:  J Leukoc Biol       Date:  2015-10-14       Impact factor: 4.962

8.  Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays.

Authors:  E Björklund; E Norén; J Nilsson; C J Fowler
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

9.  Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin.

Authors:  Xiaofan Liu; Yanping Wang; Richard I Duclos; George A O'Doherty
Journal:  ACS Med Chem Lett       Date:  2018-02-21       Impact factor: 4.345

10.  A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Authors:  Tiziana Bisogno; Anu Mahadevan; Roberto Coccurello; Jae Won Chang; Marco Allarà; Yugang Chen; Giacomo Giacovazzo; Aron Lichtman; Benjamin Cravatt; Anna Moles; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.